Safety and Efficacy of Trastuzumab BS

Back to Search
Print
Bookmark Trial

NCT04181333

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Gastric Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients with unresectable advanced/recurrent gastric cancer who are confirmed to have HER2 overexpression and started treatment with this drug*

- Patients who receive this drug* for the first time after this drug* is launched * Not including the biological product, HERCEPTIN, and biosimilars of HERCEPTIN other than this drug

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- not specified in this study

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Gastric CancerSafety and Efficacy of Trastuzumab BS
NCT04181333
ALL GENDERS
0+
years
MULTIPLE SITES
Gastric CancerStudy Evaluating Isovorin in Advanced/Recurrent Gastric Cancer
NCT00195572
  1. Adachi-ku, Tokyo,
  2. Anjo-city,
  3. Aomori-shi,
  4. Chiba-shi,
  5. Chiba,
  6. Chikushino-shi,
  7. Fukuoka,
  8. Fukuroi-shi,
  9. Funai-gun,
  10. Hiroshima-shi,
  11. Hiroshima,
  12. Ichihara-shi,
  13. Kanagawa,
  14. Kanazawa-shi,
  15. Kisaradu-shi,
  16. Kitaadachi-gun,
  17. Koto-ku, Tokyo,
  18. Kyoto,
  19. Misawa-shi,
  20. Morioka-shi,
  21. Nagasaki,
  22. Nagoya City,
  23. Nagoya,
  24. Oomura City,
  25. Osaka-si,
  26. Osaka-si,
  27. Sagamiharashi,
  28. Saga,
  29. Sapparo City,
  30. Sapporo City,
  31. Sapporo-shi,
  32. Sapporo-shi,
  33. Sasebo-shi,
  34. Sendai-shi,
  35. Sendai-shi,
  36. Shizuka,
  37. Shizuoka-shi,
  38. Sizuoka-shi,
  39. Takatuki-si,
  40. Tsuchiura-shi,
  41. Tsukuba-shi,
  42. Uji-shi,
  43. Yamagata-shi,
ALL GENDERS
20 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Safety and Efficacy of Trastuzumab BS
Official Title TRASTUZUMAB BS for Intravenous Infusion 60 mg [Pfizer], TRASTUZUMAB BS for Intravenous Infusion 150 mg [Pfizer] General Investigation (Unresectable Advanced/Recurrent HER2-Overexpressing Gastric Cancer)
Brief Summary To confirm the safety and efficacy of this drug under the actual use
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population 100 patients
Condition Gastric Cancer
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Not yet recruiting
Estimated Enrollment
 (submitted: November 26, 2019)		150
Original Estimated Enrollment Same as current
Estimated Study Completion Date February 6, 2023
Estimated Primary Completion Date February 6, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Patients with unresectable advanced/recurrent gastric cancer who are confirmed to have HER2 overexpression and started treatment with this drug*
  • Patients who receive this drug* for the first time after this drug* is launched * Not including the biological product, HERCEPTIN, and biosimilars of HERCEPTIN other than this drug

Exclusion Criteria:

- not specified in this study

Sex/Gender
Sexes Eligible for Study:All
Ages Child, Adult, Older Adult
Accepts Healthy Volunteers No
Contacts
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT04181333
Other Study ID Numbers B3271007
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date December 2020